Search results
Results From The WOW.Com Content Network
Alcon Inc. Alcon Inc. ( German: Alcon AG) is a Swiss-American pharmaceutical and medical device company specializing in eye care products. It has a paper headquarters in Geneva, Switzerland but its operational headquarters are in Fort Worth, Texas, United States, where it employs about 4,500 people. [2]
Novartis announces that it will spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to focus on its legacy pharmaceuticals business.
Pfizer: Off-label promotion of Bextra, Geodon, Zyvox and Lyrica, September 2009. In what was the largest pharmaceutical settlement in U.S. history at the time, Pfizer reached a $2.3 billion settlement with the Department of Justice to resolve criminal charges and civil claims under the False Claims Act.
Novartis. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...
Shares of Novartis (NVS) soared higher on Wednesday, after the Swiss drug maker finally obtained the remaining outstanding shares of Alcon (ACL) for $12.9 billion. Novartis had been trying to gain ...
The total cost to Novartis for the 77% stake in Alcon was $38.7 billion ($168 per share). In the deal's first phase, Novartis acquired a 25% stake in Alcon from Nestlé for $10.4 billion in July 2008.
Nepafenac, sold under the brand name Nevanac among others, is a nonsteroidal anti-inflammatory drug (NSAID), usually sold as a prescription eye drop 0.1% solution (Nevanac) or 0.3% solution (Ilevro). It is used to treat pain and inflammation associated with cataract surgery. [3] Nepafenac is a prodrug of amfenac, an inhibitor of COX-1 and COX-2 ...
The European Commission has approved the intravitreal eye injection Jetrea, produced by Novartis eye care subsidiary Alcon, for treating vitreomacular traction in the European Union. The disease ...